Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure

Journal of Cardiovascular Electrophysiology

Volumn 17, Issue 5, 2006, Pages 534-541

  Shroff, Sunil C ^a   Ryu, Kyungmoo ^b   Martovitz, Nichole L ^a   Hoit, Brian D ^a   Stambler, Bruce S ^a,c  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b Case Western Reserve University   (United States)

^c NONE   (United States)

Author keywords

Aldosterone; Electrophysiology; Heart failure; Tachyarrhythmias

Indexed keywords

ALDOSTERONE ANTAGONIST; EPLERENONE; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIASTOLE; DISEASE ASSOCIATION; DOG; ECHOCARDIOGRAPHY; ELECTROPHYSIOLOGY; HEART ATRIUM ENLARGEMENT; HEART LEFT ATRIUM; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE PACING; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SUPRAVENTRICULAR TACHYCARDIA; SYSTOLE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; DOGS; HEART ATRIA; HEART CONDUCTION SYSTEM; HEART FAILURE, CONGESTIVE; RANDOM ALLOCATION; RECEPTORS, ALDOSTERONE; SPIRONOLACTONE; TACHYCARDIA; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33645961322     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2006.00372.x     Document Type: Article

References (26)

1. Healey JS Baranchuk A Crystal E Morillo CA Garfinkle M Yusuf S Connolly SJ Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis. J Am Coll Cardiol 2005 45 1832 1839.
2. Vermes E Tardif JC Bourassa MG Racine N Levesque S White M Guerra PG Ducharme A Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003 107 2926 2931.
3. Li D Leung TK Han H Cardin S Wang Z Nattel S Effects of angiotensin converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing induced congestive heart failure. Circulation 2001 104 2608 2614.
4. Goette A Hoffmanns P Enayati W Meltendorf U Geller JC Klein HU Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol 2001 88 906 909.
5. Milliez P Girerd X Plouin PF Blacher J Safar ME Mourad JJ Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005 45 1243 1248.
6. Struthers AD MacDonald TM Review of aldosterone and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004 61 663 670.
7. Benitah JP Vassort G Aldosterone upregulates Ca2+ current in adult rat cardiomyocytes. Circ Res 1999 8512 1139 1145.
8. Benitah JP Perrier E Gomez AM Vassort G Effects of aldosterone on transient outward K+ current density in rat ventricular myocytes. J Physiol 2001 537 Pt 1 151 160.
9. Ouvrard-Pascaud A Sainte-Marie Y Benitah JP Perrier R Soukaseum C Cat AN Royer A Le Quang K Charpentier F Demolombe S Mechta-Grigoriou F Beggah AT Maison-Blanche P Oblin ME Delcayre C Fishman GI Farman N Escoubet B Jaisser F Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 2005 111 3025 3033.
10. Li D Melnyk P Feng J Wang Z Petrecca K Shrier A Nattel S The effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation 2000 101 2631 2638.
11. Stambler BS Fenelon G Shepard RK Clemo HF Guiraudon CM Characterization of sustained atrial tachycardia in dogs with rapid ventricular pacing-induced heart failure. J Cardiovasc Electrophysiol 2003 14 499 507.
12. Yee KM Pringle SD Struthers AD Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 2001 37 1800 1807.
13. Suzuki G Morita H Mishima T Sharov VG Todor A Tanhehco EJ Rudolph AE McMahon EG Goldstein S Sabbah HN Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002 106 2967 2972.
14. Pitt B Zannad F Remme WJ Cody R Castaigne A Perez A Palensky J Wittes J for the Randomized Aldactone Evaluation Study Investigators The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999 341 709 717.
15. Pitt B Remme W Zannad F Neaton J Martinez F Roniker B Bittman R Hurley S Kleiman J Gatlin M for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003 348 1309 1321.
16. Briggs A Holland W Antifibrillatory effects of electrolyte regulating esteroids on isolated rabbit atria. Am J Physiol 1959 197 1161 1164.
17. Caballero R Moreno I Gonzalez T Arias C Valenzuela C Delpon E Tamargo J Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels. Circulation 2003 107 889 895.
18. Gomez R Nunez L Caballero R Vaquero M Tamargo J Delpon E Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1+minK channels. Br J Pharmacol 2005 146 146 161.
19. Sica DA Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 2005 10 23 29.
20. Ryu K Shroff SC Sahadevan J Martovitz NL Khrestian CM Stambler BS Mapping of atrial activation during sustained atrial fibrillation in dogs with rapid ventricular pacing induced heart failure: Evidence for a role of driver regions. J Cardiovasc Electrophysiol Epub ahead of print, Sep 2, 2005. doi
21. Milliez P Deangelis N Rucker-Martin C Leenhardt A Vicaut E Robidel E Beaufils P Delcayre C Hatem SN Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 2005 26 2193 2199.
22. Beck L Blanc-Guillemaud V Cherif OK Jover B Davy JM Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction. Cardiology 2001 96 85 93.
23. Barr CS Lang CC Hanson J Arnott M Kennedy N Struthers AD Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995 76 1259 1265.
24. Perrier E Kerfant BG Lalevee N Bideaux P Rossier MF Richard S Gomez AM Benitah JP Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction. Circulation 2004 110 776 783.
25. Li D Bénardeau A Nattel S Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation. Circulation 2000 102 104 112.
26. Li D Zhang L Kneller J Nattel S Potential ionic mechanism for repolarization differences between canine right and left atrium. Circ Res 2001 88 1168 1175.